Drug
Fosmanogepix clinical trials
Also written APX001.
Keep track of what changes. Save the fosmanogepix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
APX001A (1)
Studies
Open first, then newest update. How each study uses fosmanogepix is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.RecruitingPhase 3Basilea PharmaceuticaNCT05421858Written as Fosmanogepix
- A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsRecruitingPhase 1Basilea PharmaceuticaNCT07881224Written as Fosmanogepix
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.RecruitingPhase 3Basilea PharmaceuticaNCT06925321Written as Fosmanogepix IV infusion
- A Study of Fosmanogepix in Healthy Adult Chinese SubjectsCompletedPhase 1Basilea PharmaceuticaNCT06961708Written as Oral Fosmanogepix
- A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.CompletedPhase 1Basilea PharmaceuticaNCT05582187Written as Fosmanogepix
- An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida AurisCompletedPhase 2Basilea PharmaceuticaNCT04148287Written as APX001
- An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With CandidemiaCompletedPhase 2Basilea PharmaceuticaNCT03604705Written as APX001
- Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare MoldsTerminatedPhase 2Basilea PharmaceuticaNCT04240886Written as fosmanogepix
- Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered OrallyCompletedPhase 1Basilea PharmaceuticaNCT02957929Written as APX001 single IV dose
- Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy SubjectsCompletedPhase 1Basilea PharmaceuticaNCT02956499Written as APX001 single dose 1
- A Bioequivalence Study of APX001 High-load and Low-load TabletsCompletedPhase 1Basilea PharmaceuticaNCT05491733Written as APX001
- A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001CompletedPhase 1Basilea PharmaceuticaNCT04166669Written as APX001
- A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy MalesCompletedPhase 1Basilea PharmaceuticaNCT04804059Written as [14C]-APX001 Oral Solution
Codes
What other systems call fosmanogepix · ClinicalTrials.gg INT014367
- UNII (FDA) 1XQ871489PFOSMANOGEPIXConfirmed FDA, Wikidata
- Wikidata Q112931096fosmanogepixConfirmed FDA, Wikidata
- NCI Thesaurus C155900FosmanogepixOne source FDA
- DrugBank DB15183One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1XQ871489P | FOSMANOGEPIX | Confirmed FDA, Wikidata |
| Wikidata | Q112931096 | fosmanogepix | Confirmed FDA, Wikidata |
| NCI Thesaurus | C155900 | Fosmanogepix | One source FDA |
| DrugBank | DB15183 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.